Accelerate time-to-market with defensible intellectual property assets. Each contracted research module generates complete analytical validation packages, verifiable bioactivity profiles, and reproducible commercial batch documentation.
Headquartered in Changsha, Hunan, MedGence (Yineng Pharma) operates at the strategic intersection of natural medicinal chemistry, modern pharmaceutical bioprocessing, and international patent law. Over more than 14 years, our scientific collective of 300+ research personnel has established a premier platform for original design manufacturing (ODM) backed by proprietary intellectual property (IP).
We do not merely supply generic herbal extracts. Our ODM service packages transfer or license novel extraction mechanics, non-obvious synergistic compound proportions, specialized polymorph stabilization routes, and indications supported by preclinical and clinical empirical dossiers.
Eliminate the friction between laboratory-scale innovation and commercial manufacturing. With our in-house pilot facilities and collaborative cGMP-certified industrial lines, formulation breakthroughs transition seamlessly into batch-certified commercial execution under airtight non-disclosure agreements.
Traditional remedies face global skepticism unless quantified via modern chemometrics. We validate each preparation with HPLC, HPTLC, GC-MS, and chromatographic fingerprinting to establish unambiguous chemical identities, bioequivalence, and toxicological safety profiles.
Decades of contract research collaboration with China’s premier state-owned pharmaceutical conglomerates, clinical research university hospitals, and international nutraceutical giants.
In mature pharmaceutical, dietary supplement, and dermato-cosmetic industries, generic contract manufacturing has become an operational race to the bottom. Forward-looking brand owners and pharmaceutical sponsors demand intellectual property ownership to shield pricing power and insulate market share against commodity duplication.
| Evaluation Parameter | Conventional OEM Contract Sourcing | Proprietary ODM Intellectual Property Model | Strategic Enterprise Value |
|---|---|---|---|
| Formula Exclusivity | Publicly known, generic recipes accessible to all competitors. | Patented composition or trade-secret protected extraction mechanics. | Zero cannibalization risk; defensible retail shelf and clinical premium. |
| Quality Standards | Basic assay tests; vulnerable to seasonal potency drop. | Comprehensive HPLC/HPTLC fingerprinting and geographic profiling. | Consistent biological target binding and reproducible therapeutic outcome. |
| Regulatory Readiness | Simple Certificate of Analysis (CoA) without raw data. | Full CTD dossier packages (ICH Q2 validation, toxicology, stability). | Turnkey submission for US FDA NDI, Botanical Drug IND, or EU Novel Food. |
| Commercial Asset Value | Operational expense with zero book value accretion. | Transferable patent rights, registered trademarks, clinical dossiers. | Substantial balance sheet enhancement and valuation multiple expansion. |
Modern enterprises no longer seek pure manufacturing volume; they procure regulatory certainty, validated efficacy, and defensible exclusivity. Botanical active compounds—encompassing secondary metabolites like triterpenoid saponins, flavonoids, polyphenols, and bioactive polysaccharides—exhibit profound variability influenced by geography, microclimate, and processing. MedGence solves this systemic vulnerability by converting erratic organic materials into standardized, patent-protected pharmaceutical-grade ingredients.
Our contract R&D structure unifies twelve interdependent scientific disciplines into a single accountable continuum, removing the data disintegration common when contracting disjointed CROs, assay labs, and contract factories.
Utilizing high-performance liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS), our scientific teams isolate active chemical moieties. We identify high-density botanical sources, analyzing whether wild, cultivated, or specific cultivars optimize target yields without threatening biodiversity.
Bioactive accumulation fluctuates based on harvest timing and regional soil chemistries. We track active marker concentrations across diverse geographic zones and seasonal cycles, compiling multi-year agronomic dossiers that guarantee raw material potency ceilings before extraction commences.
We formulate validated quantitative standards under ICH Q2(R1) guidelines, encompassing HPTLC qualitative fingerprint identification, reverse-phase HPLC quantitative assays, and GC residual solvent testing. These protocols furnish client quality control laboratories with legally sound release criteria.
Moving from a bench-top flask to a 10,000-liter extractor introduces thermodynamic and mass-transfer barriers. Our chemical engineers optimize dynamic countercurrent extraction, macroporous resin adsorption, ultrafiltration, and vacuum spray-drying parameters to lock in yield efficiencies.
Safety validation is non-negotiable for international marketing authorisations. We execute comprehensive in vitro cytotoxicity, bacterial reverse mutation (Ames test), mammalian chromosomal aberration assays, and in vivo rodents acute LD50, sub-chronic (90-day oral), and chronic toxicity programs.
We bridge traditional usage and modern evidence through structured Good Clinical Practice (GCP) trials. From small-cohort pharmacokinetic and pharmacodynamic (PK/PD) studies for functional health claims to multicenter Phase I–IV double-blind randomized clinical trials for botanical New Drug Applications (NDA).
Phytochemical research is undergoing an epochal transformation. By integrating high-dimensional chemometric data with computational artificial intelligence, MedGence maps multi-target network pharmacology to engineer patent-protected formulations in weeks rather than years.
Before initiating wet-lab assays, our computational models simulate interactions between complex secondary plant metabolites and targeted human protein receptors, eliminating low-affinity botanical candidates early.
Transitioning beyond hazardous organic solvents like hexane and chloroform, we leverage state-of-the-art Supercritical Fluid Extraction (SFE-CO₂) and Subcritical Water Extraction (SWE) to generate clean-label, contaminant-free active concentrates.
Overcoming the poor oral bioavailability and rapid first-pass metabolism of natural polyphenols and flavonoids through advanced nano-encapsulation, phytosome complexes, and self-emulsifying drug delivery systems (SEDDS).
Correlating wild botanical gene pathways with metabolic engineering, establishing pilot fermentation pathways for rare botanical actives while maintaining our core high-capacity agricultural extraction supply chains.
Entering international territories with natural extracts requires deep compliance fluency across divergent pharmacopeias and jurisdictional statutes. MedGence engineers every ODM research protocol to satisfy the rigorous oversight of leading global drug and health authorities.
We prepare full Chemistry, Manufacturing, and Controls (CMC) dossiers complying with the FDA Guidance for Industry: Botanical Drug Development. For functional dietary supplements, we generate authoritative New Dietary Ingredient Notifications (NDIN) and Generally Recognized as Safe (GRAS) expert panels backed by complete toxicology packages.
Our scientific reports support both Well-Established Medicinal Use and Traditional Herbal Medicinal Products (THMPD) under the European Medicines Agency (EMA). We provide validated chromatographic fingerprinting meeting European Pharmacopoeia (Ph. Eur.) monographs, residual pesticide screenings (compliant with Regulation EC No 396/2005), and heavy metal limits.
Deep expertise in National Medical Products Administration (NMPA) clinical trial filings, Hospital Preparation registrations (56 approvals secured), and Southeast Asian ASEAN harmonized standards. We ensure rapid dossier adaptation for localized Therapeutic Goods Administration (TGA) listings in Australia.
The defining risk in contract manufacturing is intellectual property leakage. MedGence maintains an inviolable entrusted contract research and manufacturing charter. Our legal frameworks guarantee that proprietary knowledge remains completely secured and client-controlled.
Under our bespoke ODM project agreements, all patents resulting from contract work—including formula composition claims, novel combination synergy discoveries, and specific therapeutic indication claims—are assigned directly to the client entity.
All pilot batch logs, chromatographic profiles, synthetic steps, and extraction parameters are segregated across isolated digital databases. Laboratory personnel are bound by stringent trade secret clauses and strict access permissions across every stage.
We work with international patent counsels to structure comprehensive claim language (such as broad Markush structures for active derivatives and narrow stoichiometric ratio boundaries) to preempt competitor design-arounds and generic encroachment.
Our analytical rigor and contract CDMO integrity have made MedGence the preferred innovation partner for premier state pharmaceutical firms, research institutes, and university clinical medical centers.
Beijing Tongrentang Group
China Resources Sanjiu
Sunflower Pharmaceutical
Livzon Pharmaceutical
Dihon Pharmaceutical
Golden Throat Holdings
Yangtzi River Pharma
Beihai Gofar Chuanshan
Humanwell Healthcare
SCIMYTH Pharmaceutical
Shandong Hanfang
Luoxin Pharmaceutical
Guangdong Zhongsheng
Hunan Brilliance
Apeloa Pharmaceutical
Hunan Heng Chang
Baotou TCM
Kamp Medicine
Guangxi Santo
Hunan Kangshou
Jiangxi Juwang
Beijing Tcmages
Guizhou Ruihe
Anhui CR Jinchan
Kangmei Pharmaceutical
Hunan Tianjicaotang
Jiangxi Kingstone Unite
Shuguang Hospital (Shanghai)
Hunan Directly Affiliated Hospital
1st Hospital Hunan TCM
2nd Xiangya Hospital
2nd Hospital Hunan TCM
Zhuzhou TCM OrthopedicsDetailed clarifications on contract structures, IP assignment, batch transfer validation, and regulatory filings for multinational buyers.
Deploy our validated research platforms, animal study models, and chromatographic profiling workflows to establish proprietary, exclusive market positions.
Discuss your target indication, therapeutic compound, or finished dosage requirement directly with our senior phytochemical team. Direct email inquiry: [email protected]
